Keyphrases
COVID-19
100%
Adverse Effects
57%
Chloroquine and Hydroxychloroquine
57%
Retrospective Cohort Study
56%
Rifampicin
50%
Tuberculosis Infection
50%
AIDS/HIV
50%
Plasma Concentration
50%
HIV Viral Load
50%
Efavirenz
50%
Pain Pharmacology
50%
Corticosteroids
50%
Genotype
50%
Prospective Survey
50%
Clopidogrel
50%
Dual Antiplatelet Therapy
50%
Narrative Review
50%
Therapeutic Efficacy
50%
Cytochrome P450 2D6 (CYP2D6)
50%
Therapeutic Effectiveness
50%
Antiviral Treatment
50%
Safety Analysis
50%
Molecular Docking
50%
Pain Management
50%
Acute Coronary Syndrome
50%
Falciparum Malaria
50%
Post-cesarean Section
50%
Leprosy Patients
50%
Clinical Pharmacology
50%
Angiotensin-converting Enzyme 2 Receptor
50%
Primaquine
50%
Quinine
50%
Aspirin
50%
Cost-effectiveness Analysis
50%
Emergency Cesarean
37%
Caesarean Operation
37%
Major Adverse Cardiovascular Events
31%
Peptidase
27%
Chloroquine
25%
Hydroxychloroquine
25%
Analgesic
25%
Experienced Pain
25%
Chi-square Test
19%
Viral Load
17%
Dextrorphan
16%
Activity Score
16%
Odds Ratio
16%
Metabolic Ratio
16%
Dextromethorphan
16%
Favipiravir
14%
Pharmacology, Toxicology and Pharmaceutical Science
Chloroquine
75%
Hydroxychloroquine
75%
Adverse Event
66%
Cohort Study
56%
Tuberculosis
50%
Efavirenz
50%
Rifampicin
50%
HIV
50%
Clopidogrel
50%
Acute Coronary Syndrome
50%
Acetylsalicylic Acid
50%
Antiplatelet
50%
CYP2D6
50%
Receptor
50%
Angiotensin Converting Enzyme 2
50%
Plasmodium Vivax Malaria
50%
Antivirus Agent
50%
Primaquine
50%
Coronavirinae
50%
Disease
50%
Clinical Pharmacology
50%
Combination Therapy
50%
Cardiovascular Disease
31%
SARS Coronavirus
30%
Peptidase
27%
Recurrent Disease
20%
Bleeding
18%
Dextrorphan
16%
Favipiravir
16%
Repurposing
16%
Oseltamivir
16%
Lopinavir Plus Ritonavir
16%
Dextromethorphan
16%
Remdesivir
16%
Infection
14%
Antimalarial Agent
11%
Side Effect
10%
Oxacillin
10%
Investigational Drug
8%
Clinical Study
8%
Pandemic
8%
Heart Arrhythmia
8%
Pharmacokinetics
6%
Melena
6%
Ticagrelor
6%
Adverse Drug Reaction
6%
Hyperuricemia
6%
Dyspnea
6%
Reinfection
5%
Case-Control Study
5%
